PIK3CA and Hyperglycemia: PI3K inhibitors such as pilaralisib and copanisib have shown a 28–30% incidence of hyperglycemia in clinical trials, while other drugs that target the same pathway such as idelalisib did not cause hyperglycemia [142,146].